CD274 and neoplasm: In contrast, many tumor types use PD-L1 IHC to guide first-line treatment decisions for anti-PD-(L)1 therapy, alone or combined with chemotherapy, particularly in tumor types where immunotherapy is not the standard of care for all patients.